AIDS Therapies

Discontinuing MAC Prophylaxis Seems Safe in HIV Patients Taking HAART

Published in TB and Outbreaks Week, September 5th, 2000

Researchers in Switzerland find that discontinuing primary prophylaxis against disseminated Mycobacterium avium infection (MAC) in HIV infected patients who are responding well to highly active antiretroviral therapy (HAART) is safe.

H. Furrer and colleagues, University Hospital of Bern, conducted a prospective, multicenter cohort study to determine if eliminating primary prophylaxis against disseminated MAC in HIV patients on HAART would be safe.

"HIV infected patients were eligible for the analysis if: (i) they had a history of at least two CD4 cell counts <50x10⁶/l; (ii) they had never had MAC; (iii) they had discontinued or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2000-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry